TNF-alpha Inhibitors

1. Front Matter

   Pages I-IX

   PDF

2. Introduction to TNF/pathophysiology of TNF

   • Patricia Malerich, Dirk M. Elston

   Pages 1-8

3. History of development of TNF inhibitors

   • Seth R. Stevens, Ting H. Chang

   Pages 9-22

4. Pharmacology of TNF inhibitors

   • Rahul Shukla, Ronald B. Vender

   Pages 23-44

5. Etanercept in rheumatology

   • Jeffrey D. Greenberg, Mitsumasa Kishimoto

   Pages 45-54

6. Etanercept in dermatology and off-label use

   • Noah Gratch, Andrew F. Alexis

   Pages 55-63

7. Infliximab in rheumatology

   • Mihaela B. Taylor, Dahlia T. Lainer

   Pages 65-81

8. Infliximab in dermatology, gastroenterology, and off-label use

   • Noah Scheinfeld

   Pages 83-99

9. Adalimumab in rheumatology

   • Harry D. Fischer

   Pages 101-105

10. Adalimumab in dermatology

    • Jennifer Clay Cather, Melodie Young

    Pages 107-114

11. A review of the safety of the tumor necrosis inhibitors infliximab, etanercept, and adalimumab

    • Jeffrey M. Weinberg

    Pages 115-127

12. Back Matter

    Pages 129-133

    PDF

Over the last decade, the advent of biologic agents has greatly revolutionized therapeutic medicine in the management of chronic inflammatory diseases, such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Elucidation of the complex web of cytokine network and the roles of these cytokines in the pat- genesis of inflammatory disorders provided one of the key catalysts for the advancement of targeted biologic therapy in autoimmune and inflammatory diseases. TNF-? is known to play a crucial role in the pathogenesis of many chronic inflammatory diseases. Elevated levels of TNF-? have been demonstrated in Crohn’s disease, psoriasis, psoriatic arthritis, and rheumatoid arthritis, sugge- ing a role for TNF-? in their pathogenesis. Although TNF-? plays a critical role in the activation of innate and acquired immune responses, the persistence of the immune response and inappropriate production of TNF-? can produce pathological changes resulting from chronic inflammation and tissue damage. The purpose of this volume is to provide a comprehensive overview of the development, pharmacology, efficacy, and safety of the currently available TNF-? inhibitors – etanercept, infliximab, and adalimumab. The initial three chapters of the volume provide a background on the field on TNF-? and its inhibition. Chapter 1 provides an introduction to TNF and reviews the pathophysiology of this cytokine. Chapter 2 then presents the h- tory of the development of TNF inhibitors. The pharmacology of these agents is reviewed in Chapter 3.

• Adalimumab
• Arthritis
• Etanercept
• Infliximab
• Inhibitors
• Pharmacology
• pathophysiology
• physiology

• Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, New York, USA

  Jeffrey M. Weinberg, Robin Buchholz

Policies and ethics